ErSO-related Compounds

In collaboration with the laboratory of Prof. David Shapiro (UIUC Biochemistry) we have discovered a family of potent and selective anticancer agents, headlined by the compound ErSO.  ErSO and its derivatives induce quantitative tumor regression in certain xenograft models and have tremendous translational potential.

Related Publications

  1. Plasma Membrane Channel TRPM4 Mediates Immunogenic Therapy-Induced Necrosis
    Ghosh S, Yang R, Duraki D, Zhu J, Kim JE, Jabeen M, Mao C, Dai X, Livezey MR, Boudreau MW, Park BH, Nelson ER, Hergenrother PJ, Shapiro DJ
    Cancer Res. 2023, 83, 3115-3130

  1. Evolution of 3-(4-hydroxyphenyl)indoline-2-one as a scaffold for potent and selective anticancer activity
    Boudreau, M.W. and Hergenrother, P.J.
    RSC Med. Chem. 202213, 711-725

Link to journal
Article PDF

  1. Activators of the anticipatory unfolded protein response with enhanced selectivity for estrogen receptor positive breast cancer
    Boudreau, M.W.; Mulligan, M.P.; Shapiro, D.J.; Fan, T.M.; Hergenrother, P.J.
    J. Med. Chem. 202265, 3894-3912

  1. A small molecule activator of the unfolded protein response eradicates human breast tumors in mice
    Boudreau, MW; Duraki, D; Wang, L.; Mao, C.; Kim, J.E.; Tang, B.; Fanning, S.W.; Kiefer, J.; Tarasow, T.M.; Bruckheimer, E.M.; Moreno, R.; Mousses, S.; Greene, G.L.; Roy, E.J.; Park, B.H.; Fan, T.M.; Nelson, E.R.; Hergenrother, P.J.; Shapiro, D.J.
    Science Transl. Med. 2021, 13, eabf1383